HEMGENIX Patent Extension Period Set by FDA Regulators
Published Date: 7/14/2025
Notice
Summary
The FDA has officially set the review period for HEMGENIX, a special medicine made from human biological material. This means the company can ask for extra time on their patent to protect their invention. If approved, this extension helps the makers keep their exclusive rights longer, which can impact when generic versions hit the market and affect money flow in the drug world.
Analyzed Economic Effects
2 provisions identified: 1 benefits, 1 costs, 0 mixed.
FDA OKs Patent Extension Filing
The FDA has determined the regulatory review period for HEMGENIX, a medicine made from human biological material. Because of that determination, the company can submit an application to the U.S. Patent and Trademark Office (USPTO) to ask for extra time on a patent that claims HEMGENIX.
Possible Delay of Generic Competition
If the USPTO approves a patent extension for HEMGENIX, the maker could keep exclusive rights longer. You may pay higher prices or wait longer for lower-cost generic versions because this extension can affect when generics enter the market and the flow of money in the drug market.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Take It Personal
Get Your Personalized Policy View
Start a Free Government Policy Watch to see how policy affects your household, then upgrade to PRIA Full Coverage for year-round monitoring.
Already have an account? Sign in